ELISA/assay

Human Fibroblast growth factor receptor 3, FGFR3 ELISA Kit

MBS906230

48-Strip-Wells

510 USD

ELISA Kit

Human Fibroblast growth factor receptor 3, FGFR3 ELISA Kit

fibroblast growth factor receptor 3

Human Fibroblast growth factor receptor 3 (FGFR3) ELISA kit; ACH; CD333; CEK2; HSFGFR3EX; JTK4; OTTHUMP00000149958; OTTHUMP00000149959; achondroplasia; thanatophoric dwarfism; hydroxyaryl-protein kinase; tyrosine kinase JTK4; fibroblast growth factor receptor 3

fibroblast growth factor receptor 3 isoform 1; Fibroblast growth factor receptor 3; fibroblast growth factor receptor 3; FGFR-3; tyrosine kinase JTK4; hydroxyaryl-protein kinase; fibroblast growth factor receptor 3 variant 4; fibroblast growth factor receptor 3; CD_antigen: CD333

FGFR3

FGFR3; FGFR3; ACH; CEK2; JTK4; CD333; HSFGFR3EX; JTK4; FGFR-3

FGFR3_HUMAN

Human

806

This assay has high sensitivity and excellent specificity for detection of human FGFR3. No significant cross-reactivity or interference between human FGFR3 and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Assay Type: Sandwich. Detection Range: 62.5 pg/ml -4000 pg/ml. Sensitivity: 15.6 pg/ml.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the Assay This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for FGFR3 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any FGFR3 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for FGFR3 is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of FGFR3 bound in the initial step. The color development is stopped and the intensity of the color is measured.

4503711

NP_000133.1

NM_000142.4

P22607

87,710 Da

Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Downstream Signaling Of Activated FGFR Pathway (160957); Endochondral Ossification Pathway (198812); Endocytosis Pathway (102279); Endocytosis Pathway (102181); FGFR Ligand Binding And Activation Pathway (106344); FGFR3 Ligand Binding And Activation Pathway (106352); FGFR3b Ligand Binding And Activation Pathway (106353); FGFR3c Ligand Binding And Activation Pathway (106354)

This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. Three alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq, Jul 2009]

FGFR3: a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer. Protein type: EC 2.7.10.1; Protein kinase, TK; Kinase, protein; Membrane protein, integral; Protein kinase, tyrosine (receptor); TK group; FGFR family. Chromosomal Location of Human Ortholog: 4p16.3. Cellular Component: Golgi apparatus; internal side of plasma membrane; transport vesicle; cell surface; focal adhesion; integral to plasma membrane; endoplasmic reticulum; perinuclear region of cytoplasm; lysosome; extracellular region; plasma membrane; nucleus. Molecular Function: protein binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; protein-tyrosine kinase activity; ATP binding. Biological Process: peptidyl-tyrosine phosphorylation; nerve growth factor receptor signaling pathway; somatic stem cell maintenance; protein amino acid autophosphorylation; negative regulation of transcription from RNA polymerase II promoter; bone mineralization; positive regulation of tyrosine phosphorylation of Stat3 protein; substantia nigra development; inner ear receptor cell differentiation; cell-cell signaling; positive regulation of MAPKKK cascade; positive regulation of neuron apoptosis; positive regulation of cell proliferation; forebrain development; chondrocyte differentiation; morphogenesis of an epithelium; response to axon injury; skeletal development; negative regulation of epithelial cell proliferation; endochondral ossification; negative regulation of developmental growth; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; myelination in the central nervous system; MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; digestive tract morphogenesis; JAK-STAT cascade; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of protein ubiquitination; negative regulation of smoothened signaling pathway; negative regulation of mitosis; negative regulation of astrocyte differentiation; insulin receptor signaling pathway; innate immune response; positive regulation of endothelial cell proliferation; lens morphogenesis in camera-type eye; positive regulation of cell differentiation. Disease: Bladder Cancer; Camptodactyly, Tall Stature, And Hearing Loss Syndrome; Lacrimoauriculodentodigital Syndrome; Achondroplasia; Hypochondroplasia; Muenke Syndrome; Thanatophoric Dysplasia, Type Ii; Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans; Cervical Cancer; Thanatophoric Dysplasia, Type I; Crouzon Syndrome With Acanthosis Nigricans; Colorectal Cancer; Testicular Germ Cell Tumor; Nevus, Epidermal

48-Strip-Wells

510 USD

96-Strip-Wells

725

5x96-Strip-Wells

2565

10x96-Strip-Wells

4800